Clinical data | |
---|---|
Routes of administration | Inhalation |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C13H22N4O7 |
Molar mass | 346.340 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Laninamivir (CS-8958) is a neuraminidase inhibitor that is a drug used for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. [1] It is currently in Phase III clinical trials. [2] It is a long-acting neuraminidase inhibitor administered by nasal inhalation. [3]
Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals [4] and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US. [5] It is under clinical evaluations in other countries. [3] [6]
Clinical data | |
---|---|
Routes of administration | Inhalation |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C13H22N4O7 |
Molar mass | 346.340 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Laninamivir (CS-8958) is a neuraminidase inhibitor that is a drug used for the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. [1] It is currently in Phase III clinical trials. [2] It is a long-acting neuraminidase inhibitor administered by nasal inhalation. [3]
Laninamivir was approved for influenza treatment in Japan in 2010 and for prophylaxis in 2013. It is currently marketed under the name Inavir by Daiichi Sankyo. Biota Pharmaceuticals [4] and Daiichi Sankyo co-own Laninamivir. On 1 April 2011, BARDA awarded up to an estimated U$231m to Biota Pharmaceuticals (Formerly Biota Holdings Ltd) wholly owned subsidiary, Biota Scientific Management Pty Ltd, for the advanced development of Laninamivir in the US. [5] It is under clinical evaluations in other countries. [3] [6]